RxDoctor Payments Data

Ekua McCalla

Nurse Practitioner · Falls Church, VANPI 1386015816

Payments from drug & device makers

$1,160in general payments, 2019–2025

Across 53 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$339
  • Lilly USA, LLC$154
  • Novo Nordisk$153
  • Astellas Pharma US Inc$113
  • Merck$70
  • Boehringer Ingelheim$64
  • plus $267 from 9 others

What the payments were for

  • Food & beverage$1,160100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer15$339
Lilly USA, LLC7$154
Novo Nordisk7$153
Astellas Pharma US Inc6$113
Merck3$70
Boehringer Ingelheim3$64
AbbVie2$59
Exact Sciences2$46
Amgen2$35
VBI Vaccine (delaware) Inc.1$25
Dynavax Technologies Corporation1$24
Hologic Sales And Service, LLC1$22
Watermark Medical, Inc.1$20
Organon1$18
Seqirus USA Inc1$18

How this compares

$1,160 in reported general payments places this provider in the 80th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$29,587
Medicare patients
181
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$13,893
Bupropion XlBupropion Hcl17$1,537
SynthroidLevothyroxine Sodium14$1,368
Atorvastatin Calcium83$621
Rosuvastatin Calcium36$585
Levothyroxine Sodium53$573
Fluticasone Propionate23$543
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide13$426
Lisinopril70$423
Pantoprazole Sodium14$313
Montelukast Sodium15$310
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide14$290
Losartan Potassium43$279
Trazodone Hcl26$266
Amlodipine Besylate36$253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$339$13,89317 claims
AbbVieSynthroid$59$1,36814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Falls Church

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →